Audit: QRS - Alpha-Lactalbumin for Health & Longevity
Audit conducted on 18/09/2026 05:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (40 g two hours before bed; 20–60 g; 3.5 h window; 20 g post-exercise + 40 g pre-sleep), all 6 contraindications, all 10 interactions, all 4 benefit tiers, all 4 risk tiers, all 9 monitoring rows, the cadence sentence and all 6 qualitative items trace to ER text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “morning dosing not tested for sleep or mood” mirrors ER line 366; “no long-term data” mirrors ER line 155; “a plausible tool with thin support” is ER line 488 verbatim. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | MAOI use stays in the Contraindications gate (ER line 309 “Absolute contraindication”); the conflicted sleep signal is carried as “the sleep findings disagree” in the lede. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gate content comes only from ER Key Interactions & Contraindications (lines 305–334); benefits from Expected Benefits; risks from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor bullet appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs or author names in the QRS. Brand/drug names (Sinemet, Madopar, sertraline, venlafaxine, alendronate, doxycycline, ciprofloxacin, insulin, glimepiride, dextromethorphan, St John’s wort, calcium carbonate, omeprazole, melatonin, valerian, glycine) all appear in ER lines 305–323 for the same interaction. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No researcher, institution or manufacturer attribution appears anywhere in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register throughout, matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and doses alongside plain-language framing; no hype and no discouragement. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | All cells are noun phrases stating what the evidence shows, not instructions to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring targets are stated as ranges from the ER’s own “Optimal Functional Range” column; no prescriptive verbs. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, “advise” or comparable framing in any span. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Acronyms expanded as in the ER: “Immunoglobulin E”, “Estimated glomerular filtration rate”, “Insulin-like growth factor 1”, “High-sensitivity C-reactive protein”; “tryptophan-to-LNAA ratio” rendered as “ratio of tryptophan to competing amino acids”. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is a bare phrase; the six Low benefits are packed into one semicolon-separated line. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”: no occurrences. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Nine-marker monitoring panel, cystatin C-based filtration rate and component allergen testing presuppose a proactive, self-quantifying reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A 40 g nightly evening dose timed 90–120 minutes before sleep plus a split training-support regimen assumes that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content density and biomarker specificity place it well beyond general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede names the responder subgroup (“only in those prone to stress or low mood”) and the conflicted sleep evidence, exactly the distinction this audience needs. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Full-text scan: no occurrence of “anti-aging”. Title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. This holds on EVERY surface. Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“sensitisation”, “anaphylaxis”, “muscle protein synthesis”, “sleep-onset latency”); no consumer-grade substitutes for route or dose form. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fifteen fixed strings verified byte-for-byte against the template (QRS lines 445, 488, 536, 564, 582, 610, 638, 642–644, 760 and the eight tier labels). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names present; the repeatable marker_#_* row is instantiated 9× and qualitative_item_# 6×. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Normalized structural diff against the template shows differences only inside data-qrs-var spans and in the repeated marker/qualitative rows; website="evidence_review", website="audit" and website="full_review" spans, the stylesheet link and the footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that feeds the QRS is empty; every tier, gate, monitoring and qualitative source list is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard evening dose”, “Best time of day” and “Training-support regimen” reproduce ER bold labels at lines 358, 366 and 360 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | The three protocol labels are ER labels verbatim; the Time-to-Effect labels (“Memory”, “Mood and cortisol”, “Sleep onset”) name the ER benefit each timing belongs to, and the ER supplies no bold label for them. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan of the emoji and dingbat ranges returns no match; the ER’s 🟩/🟥/🟨 and ⚠️ markers were all dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its minimum faithful form — bare noun phrases, six Low benefits on one line, three-to-six-word “Why” cells — with no explanatory prose carried over. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” caption precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element in <body> repeats any frontmatter value. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: alpha_lactalbumin_2026-0918-0123_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0918-0420, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no context-window or other qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys, including the added git_user and git_issue values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Alpha-Lactalbumin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Alpha-Lactalbumin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/18/2026”, the correct reformat of 2026-0918-0420. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template’s standard subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs (ER lines 482–488): the tryptophan premise, the responder-limited memory and stress findings, the disagreeing sleep evidence, and the closing verdict. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 51 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Tryptophan/serotonin premise and the two-hour window → ER 482; responder-limited memory and mood → ER 484; sleep disagreement → ER 484; evening dosing → ER 366; “a plausible tool with thin support” → ER 488. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms at all; “tryptophan” and “serotonin” are replaced by “the amino acid the brain uses to build mood and sleep signals”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No author, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result; the only figure is the two-hour timing, which is a kinetic window rather than an effect size. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from the “Populations who should avoid Alpha-Lactalbumin” list at ER lines 329–334. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations are present: milk protein allergy, phenylketonuria, classic galactosemia, CKD stage 4–5, monoamine oxidase inhibitor use, levodopa-treated Parkinson’s disease. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six discrete <li> elements at QRS lines 567–577. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing em-dash clauses on phenylketonuria and galactosemia (lines 330–331) are stripped; the only en-dash left is inside the range “stage 4–5”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(below 30 mL/min/1.73 m²)” retained; “stage 4–5”, “on protein restriction”, “especially with prior anaphylaxis” and “unless separated under specialist supervision” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and correctly so — the ER names six such populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map one-to-one onto ER bullets at lines 305–325. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten of the ER’s eleven interaction bullets are carried; the monoamine oxidase inhibitor bullet (ER line 309, “Absolute contraindication”) is correctly excluded because it already sits in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten discrete <li> elements at QRS lines 585–600. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “Caution/Monitor — … Mitigation: …” tail is stripped; no item carries a dash-introduced clause. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER parenthetical survives in shortened form: (Sinemet, Madopar); (sertraline, venlafaxine); (alendronate, doxycycline, ciprofloxacin); (insulin, glimepiride); (dextromethorphan, St John’s wort); (calcium carbonate, omeprazole); (melatonin, valerian, glycine). None dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and correctly so — the ER names eleven interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol bullets at lines 358, 360 and 366. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard evening dose, best time of day and the training-support regimen are the three bullets that state an executable dose or timing; the remaining ER bullets cover kinetics, competing schools of thought and modifier caveats. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated: doses (40 g; 20–60 g; 20 g + 40 g), timing (2 h before bed; 90–120 min; post-exercise) and the over-65 caveat from ER line 376. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Memory, mood/cortisol and sleep onset — the three outcomes for which ER lines 413 and 155 give an onset window. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Memory (ER High tier) → mood and cortisol (Medium) → sleep onset (Low), matching the ER’s benefit ranking exactly. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; the 90–120 minute peak in time_3_sub comes from ER line 413. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (lines 155, 413), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All twelve benefit phrases are the ER’s own Expected Benefits sub-headings (lines 153–217), condensed to sentence case. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at QRS lines 538–557. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every Magnitude: paragraph and every trial description is dropped; each tier is a bare semicolon-separated list of outcome names. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefit span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER tiers contain items (1 High, 1 Medium, 6 Low, 3 Speculative), so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven risk phrases are the ER’s own sub-headings (lines 243–285). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at QRS lines 612–632. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The jump-height, awakening-count and prevalence figures from the ER magnitude paragraphs are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risk span; the ER’s inline glosses (“hives”, “actigraphy”, “Bos d 4”) are not carried into the tiers. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER tiers contain items (2 High, 1 Medium, 2 Low, 2 Speculative), so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All nine rows derive from the ER Monitoring Protocol & Defining Success table at lines 439–449. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present with matching optimal ranges: sleep-onset latency, PSQI, tryptophan ratio, estimated glomerular filtration rate, blood urea nitrogen, IGF-1, fasting insulin, hs-CRP, milk-specific immunoglobulin E. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces ER line 437: sleep metrics continuously with comparison at 2 and 6 weeks; blood markers at 3 months, then every 6–12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the qualitative-markers list at ER lines 453–458. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: morning alertness, ease of falling asleep, mood steadiness, next-day power and coordination, gastrointestinal symptoms, dream intensity and awakenings. |
Issues 18/09/2026 05:06
Pass rate 100.00%. No issues found.
Issues 18/09/2026 04:56
- 4.5 — Sheet overflows one A4 page: At the template’s print geometry the body measures roughly 1,470 pt against about 774 pt of usable A4 height, so the sheet runs onto a second page; the Monitoring table (lines 644-753) and the Key Interactions gate (lines 589-606, 19 wrapped lines) are the largest contributors, and several items carry avoidable words such as “levodopa–carbidopa combinations” (line 590), four spelled-out drug-class names (line 592) and three-line protocol sub-lines (lines 455-457, 469-472, 483-485).
Fixes 18/09/2026 04:56
- 4.5 — Key Interactions gate condensed: Trimmed the ten interaction items from 19 to 17 wrapped lines — “levodopa–carbidopa combinations” to “levodopa–carbidopa”, the two spelled-out reuptake-inhibitor classes merged into one with two example drugs, the four drug classes on the absorption bullet given a single shared example list, and “Over-the-counter” plus surplus examples (famotidine, magnesium glycinate) dropped; every ER parenthetical retains at least one example drug.
- 4.5 — Contraindications gate condensed: Shortened three items — “estimated filtration rate below 30” to “below 30 mL/min/1.73 m²”, “Anyone taking a monoamine oxidase inhibitor” to “Monoamine oxidase inhibitor use”, and “unless dosing is separated under specialist supervision” to “unless separated under specialist supervision”.
- 4.5 — Protocol sub-lines shortened: Reduced all three action sub-lines from three wrapped lines to two (“Alpha-lactalbumin-enriched whey” to “Enriched whey”, “Immediately post-exercise” to “Post-exercise”, “Used during intensified training blocks; upper end of the range for adults over 65” to “During intensified training blocks; upper end of range over 65”).
- 4.5 — Monitoring table condensed: Cut the table body from 16 to 13 wrapped lines by shortening five “Why” cells, the IGF-1 target to “Mid age-adjusted range”, and marker 9’s name to “Milk-specific immunoglobulin E (Bos d 4)”, leaving all nine biomarkers and their targets in place.
Issues 18/09/2026 04:45
- 1.1 — Monitoring rationale overstates ER: [marker_1_why] at QRS line 661 reads “The metric most improved in the trials”, whereas the ER (line 441) says “The single metric most consistently improved in the trials”; dropping “consistently” turns a statement about replication into one about effect magnitude that the ER contradicts elsewhere (“small, inconsistent”, ER line 177).
Fixes 18/09/2026 04:45
- 1.1 — Monitoring rationale overstates ER: Changed [marker_1_why] from “The metric most improved in the trials” to “The metric most consistently improved in the trials”, restoring the ER’s claim about replication across trials rather than effect magnitude.
Issues 18/09/2026 04:34
- 4.5 — Sheet overruns one A4 page: The rendered sheet is roughly twice the one-page budget (~1,550pt of content against ~774pt of printable height; 5,817 visible characters in narrow multi-column regions), with the excess concentrated in [monitoring_cadence] (lines 793-797), the trailing rationale clauses on all six [qualitative_item_#] entries (lines 806-836), [marker_3_target] (lines 695-697), the four-line drug parentheticals in [caution_items] (lines 596-602) and [action_3_sub] (lines 483-486).
Fixes 18/09/2026 04:34
- 4.5 — Monitoring cadence condensed: [monitoring_cadence] cut from 260 to 137 characters, from “Sleep metrics reviewed continuously, with a formal comparison at 2 weeks and 6 weeks against the pre-treatment baseline; blood markers repeated at 3 months and then every 6–12 months, or annually where baseline values were unremarkable.” to “Sleep metrics continuously, with formal comparison against baseline at 2 and 6 weeks; blood markers at 3 months, then every 6–12 months.”
- 4.5 — Monitoring table rows tightened: [marker_1_name], [marker_1_why], [marker_3_target], [marker_5_why], [marker_6_target], [marker_6_why], [marker_7_why] and [marker_8_why] were shortened to single-line cells (e.g. “Screens for the low-grade inflammation that dairy intolerance can raise” to “Screens for low-grade inflammation”), removing roughly five rendered lines from the table. All nine biomarkers and their targets remain listed.
- 4.5 — Qualitative item rationale stripped: The trailing study-rationale clauses were removed from five of the six [qualitative_item_#] entries (e.g. “Morning alertness in the first hour after waking, which is where the laboratory trial found its effect” to “Morning alertness in the first hour after waking”). All six ER markers remain.
- 4.5 — Drug parentheticals trimmed: Example drug lists in [caution_items] were shortened where the ER gave three or more exemplars (“fluoxetine, sertraline, escitalopram” to “fluoxetine, sertraline”; “alendronate, risedronate” to “alendronate”; “sulfonylureas such as glimepiride” to “glimepiride”), cutting three rendered lines. All ten interactions remain, each still carrying at least one named example.
- 4.5 — Contraindication items condensed: [stop_items] entries 1 and 4 were tightened (“especially with any prior anaphylaxis to milk” to “especially with prior anaphylaxis”; “estimated glomerular filtration rate below 30 mL/min/1.73 m²” to “filtration rate below 30 mL/min/1.73 m²”), preserving the staging, threshold and severity qualifiers. All six contraindications remain.
- 4.5 — Lede and protocol cells shortened: [at_a_glance] reduced from 56 to 51 words, [action_1_sub] and [action_3_sub] trimmed of restatement, and [time_3_sub] reduced to the 90–120 min peak alone.
- 4.5 — Benefit lists compacted: [benefits_low] and [benefits_speculative] were tightened without dropping any tier item (e.g. “glutathione support through cysteine delivery” to “glutathione support through cysteine”).
Overall the sheet’s visible text fell from 5,817 characters / 796 words to 5,018 characters / 686 words, with all mandated content retained: nine biomarkers, six qualitative markers, six contraindications, ten key interactions, all four benefit tiers and all four risk tiers.
Issues 18/09/2026 04:26
- 10.4 — Split-dosing text in wrong cell:
action_3_sub(line 484) carries the ER’s separate “Single versus split dosing” bullet into the “Training-support regimen” cell, so the sheet states “single doses throughout the literature, splitting flattens the amino acid peak” directly beneath its own two-dose value “20 g post-exercise + 40 g pre-sleep” (line 480).
Fixes 18/09/2026 04:26
- 10.4 — Split-dosing text in wrong cell: Replaced
action_3_subso the “Training-support regimen” cell no longer carries the ER’s separate “Single versus split dosing” bullet; it now reads “Regimen used during intensified training blocks; sits at the upper end of the range for adults over 65, whose anabolic sensitivity is blunted”, drawn from the ERTherapeutic Protocolage-related considerations bullet.